Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Benralizumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: Benralizumab. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2019-001800-39 Sponsor Protocol Number: D3251C00014 Start Date*: 2019-11-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to V...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) BE (Ongoing) GR (Trial now transitioned) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001832-77 Sponsor Protocol Number: D3253C00001 Start Date*: 2019-12-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab compared to Mepolizumab in the treatment of Eosinophilic...
    Medical condition: Eosinophilic Granulomatosis with Polyangiitis (EGPA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000085-14 Sponsor Protocol Number: D3258C00001 Start Date*: Information not available in EudraCT
    Sponsor Name:AstraZeneca AB
    Full Title: A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled 3-Part Phase 3 Study to Demonstrate the Efficacy and Safety of Benralizumab in Patients with Eosinophilic Gastritis and/...
    Medical condition: Eosinophilic Gastritis and/or Gastroenteritis
    Disease: Version SOC Term Classification Code Term Level
    23.0 10017947 - Gastrointestinal disorders 10083619 Eosinophilic gastritis PT
    20.1 10017947 - Gastrointestinal disorders 10017902 Gastroenteritis eosinophilic PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) NL (Completed) PL (Completed) IT (Ongoing) FR (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004590-27 Sponsor Protocol Number: D3251C00003 Start Date*: 2014-07-23
    Sponsor Name:AstraZeneca
    Full Title: Randomised, double-blind, 56 week placebo-controlled, parallel group, multicentre, phase 3 study to evaluate the efficacy and safety of 2 doses of benralizumab in patients with moderate to very sev...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) GB (Completed) IT (Completed) NL (Completed) PL (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-003763-22 Sponsor Protocol Number: 1.027.19 Start Date*: 2020-01-23
    Sponsor Name:Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside
    Full Title: A Pragmatic Proof of Concept Study to Evaluate the Effect of Benralizumab on Mannitol Challenge in Severe Eosinophilic Asthma
    Medical condition: Severe Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-001086-27 Sponsor Protocol Number: D3250C00021 Start Date*: 2014-11-07
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inh...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) PL (Completed) DE (Completed) SE (Completed) BG (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004638-40 Sponsor Protocol Number: D3250C00025 Start Date*: 2020-02-14
    Sponsor Name:AstraZenenca AB
    Full Title: An Open-label Study to Evaluate the Pharmacokinetics and Pharmacodynamics and Long-term Safety of Benralizumab Administered Subcutaneously in Children with Severe Eosinophilic Asthma.
    Medical condition: Severe Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000578-31 Sponsor Protocol Number: Rostock-Benralizumab-2018-1 Start Date*: 2018-07-05
    Sponsor Name:University Medicine Rostock
    Full Title: Impact of benralizumab treatment on circulating dendritic cells in patients with eosinophilic asthma
    Medical condition: Eosinophilic Asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003699-11 Sponsor Protocol Number: GN17RM684 Start Date*: 2019-06-13
    Sponsor Name:NHS Greater Glasgow and Clyde
    Full Title: Asthma Exacerbation Profile in patients on open label treatment with Benralizumab for severe eosinophilic asthma - an exploratory cohort study
    Medical condition: Severe Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-002871-32 Sponsor Protocol Number: D3255C00001 Start Date*: 2020-02-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis (MESSINA)
    Medical condition: Eosinophilic Esophagitis (EoE)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10064220 Eosinophilic esophagitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Ongoing) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000195-38 Sponsor Protocol Number: D3252C00004 Start Date*: 2020-11-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab for the Prevention of Recurrence of Nasal Polyps Following Surgical Rem...
    Medical condition: Nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10028754 Nasal polyp LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004579-11 Sponsor Protocol Number: D3251C00004 Start Date*: 2014-07-11
    Sponsor Name:AstraZeneca
    Full Title: A randomised, double-blind, double dummy, 56 week placebo-controlled, multicentre, parallel group, phase 3 study evaluating efficacy and safety of 3 benralizumab doses in patients with moderate to ...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) BE (Completed) PL (Completed) BG (Completed) FR (Completed) SI (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000702-38 Sponsor Protocol Number: D3250C00036 Start Date*: 2017-07-06
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomised, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium to High-dose Inhaled Corticosteroid Plus Lon...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-002039-27 Sponsor Protocol Number: D3254C00001 Start Date*: 2020-01-09
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients wi...
    Medical condition: Hypereosinophilic Syndrome (HES)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Ongoing) BE (Ongoing) AT (Ongoing) PL (Ongoing) DK (Ongoing) IT (Ongoing) NL (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005396-25 Sponsor Protocol Number: D3250C00037 Start Date*: 2016-06-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Open-label, Safety Extension Study with Benralizumab (MEDI-563) for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist (MELTEMI)
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) CZ (Completed) PL (Completed) BG (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-002818-13 Sponsor Protocol Number: DEALSZ-2021-001 Start Date*: 2023-05-12
    Sponsor Name:Charité-Universitätsmedizin Berlin
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 2, 12-Week Treatment Study with a 10-Week Follow-up Period to Assess the Efficacy and Safety of Benralizumab (anti-IL5Rα) in Adult Patients wit...
    Medical condition: Chronic prurigo in adult patients. Chronic Prurigo is characterized by the presence of chronic pruritus, multiple localized or generalized, pruriginous lesions, and the history and/or signs of a p...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037083 Prurigo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000169-17 Sponsor Protocol Number: D3259C00001 Start Date*: 2020-12-01
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2b Multinational, Randomized, Double-blind, Parallel Group, 24-week Placebo-controlled Study with 28-week Extension to Investigate the Use of Benralizumab in Patients with Chronic Spontaneo...
    Medical condition: chronic spontaneous urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10046735 Urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003665-10 Sponsor Protocol Number: RBH2017/001 Start Date*: 2020-02-25
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust
    Full Title: A single-centre study of the relationship between eosinophil activation and the lung microbiome in severe eosinophilic asthma (SEA) and the effect of benralizumab on these factors
    Medical condition: Severe Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-000287-32 Sponsor Protocol Number: D325AC00002 Start Date*: 2020-12-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid (FJORD)
    Medical condition: Bullous Pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) DE (Prematurely Ended) FR (Ongoing) IT (Prematurely Ended) GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002094-36 Sponsor Protocol Number: D3250C00038 Start Date*: 2016-11-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function with Benralizumab in Severe, U...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:21:01 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA